With fast track designation in hand, a successful protocol discussion with fda, and cros in place, biodexa is on track to initiate its funded phase 3 trial in fap next quarter

Cardiff, united kingdom / access newswire / march 19, 2025 / biodexa pharmaceuticals plc. (nasdaq:bdrx), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is making progress in readying the launch of a phase 3 trial for erapa, its proprietary encapsulated form of rapamycin being developed for the treatment of familial adenomatous polyposis (fap).
BDRX Ratings Summary
BDRX Quant Ranking